|Bid||5,049.00 x 6100|
|Ask||5,050.00 x 13000|
|Day's Range||5,036.00 - 5,155.00|
|52 Week Range||4,136.50 - 5,520.00|
|PE Ratio (TTM)||18.09|
|Forward Dividend & Yield||2.79 (4.51%)|
|1y Target Est||N/A|
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.
U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.
The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.
The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene. The drug belongs to a class of drug known as PARP inhibitors that has already been used to treat advanced BRCA-mutated ovarian cancer, the FDA said. This is the first time a PARP inhibitor has been approved to treat breast cancer and the first time any drug has been approved to treat certain patients with metastatic breast cancer associated with the same genetic mutation.
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union. The EU recommended 92 new drugs including generics, up from 81, and China laid out plans to speed up approvals in what is now the world's second biggest market behind the United States.
AstraZeneca and Novo Nordisk pulled upgrades on Friday as analysts looked ahead to key 2018 clinical trial readouts in ovarian cancer and diabetes.
We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AstraZeneca Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Wall Street analysts estimate AstraZeneca (AZN) will report earnings per share (or EPS) of $0.71 on revenues of $6.0 billion during 3Q17, 4.4% growth as compared to revenues of $5.7 billion during 3Q16....
There are a number of reasons that attract investors towards large-cap companies such as AstraZeneca PLC (LSE:AZN), with a market cap of £62.56B. One such reason is its ‘too bigRead More...
AstraZeneca’s (AZN) other products portfolio includes various drugs for infections, neuroscience drugs, and gastrointestinal drugs.
The CVMD segment reported revenues of $1.8 billion during 3Q17, a 4% decline in operating revenues driven by lower sales of Bydureon, Crestor, Onglyza, and Seloken.
In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.
This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.
The oncology segment reported revenues of $1.0 billion during 3Q17, 19% growth in operating revenues as compared to 3Q16.